THALOMID: 179 Adverse Event Reports & Safety Profile
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
179
Total FAERS Reports
34 (19.0%)
Deaths Reported
48
Hospitalizations
179
As Primary/Secondary Suspect
6
Life-Threatening
8
Disabilities
First Report: 200409 · Latest Report: 20140610
What Are the Most Common THALOMID Side Effects?
#1 Most Reported
Toxicity to various agents
30 reports (16.8%)
#2 Most Reported
Unevaluable event
25 reports (14.0%)
#3 Most Reported
Plasma cell myeloma
25 reports (14.0%)
All THALOMID Side Effects by Frequency
| Side Effect | Reports | % of Total | Deaths | Hosp. |
|---|---|---|---|---|
| Toxicity to various agents | 30 | 16.8% | 0 | 0 |
| Plasma cell myeloma | 25 | 14.0% | 8 | 4 |
| Unevaluable event | 25 | 14.0% | 1 | 0 |
| Death | 8 | 4.5% | 8 | 1 |
| Neuropathy peripheral | 8 | 4.5% | 0 | 3 |
| Haemorrhage | 6 | 3.4% | 4 | 0 |
| Deep vein thrombosis | 5 | 2.8% | 0 | 4 |
| Drug dose omission | 5 | 2.8% | 1 | 2 |
| Fatigue | 5 | 2.8% | 2 | 1 |
| Renal disorder | 5 | 2.8% | 2 | 2 |
Who Reports THALOMID Side Effects? Age & Gender Data
Gender: 100.0% female, 0.0% male. Average age: 67.3 years. Most reports from: US. View detailed demographics →
Is THALOMID Getting Safer? Reports by Year
| Year | Reports | Deaths | Hosp. |
|---|---|---|---|
| 2004 | 1 | 0 | 1 |
| 2005 | 3 | 0 | 3 |
| 2007 | 2 | 0 | 0 |
| 2008 | 2 | 0 | 1 |
| 2009 | 1 | 0 | 0 |
| 2011 | 3 | 0 | 0 |
| 2012 | 14 | 2 | 4 |
| 2013 | 30 | 10 | 13 |
| 2014 | 27 | 12 | 5 |
What Is THALOMID Used For?
| Indication | Reports |
|---|---|
| Plasma cell myeloma | 146 |
THALOMID vs Alternatives: Which Is Safer?
THALOMID vs THEOPHYLLINE
THALOMID vs THEOPHYLLINE ANHYDROUS
THALOMID vs THIAMINE
THALOMID vs THIOCOLCHICOSIDE
THALOMID vs THIOGUANINE
THALOMID vs THIOGUANINE ANHYDROUS
THALOMID vs THIOPENTAL
THALOMID vs THIORIDAZINE
THALOMID vs THIOTEPA
THALOMID vs THIOTHIXENE
Official FDA Label for THALOMID
Official prescribing information from the FDA-approved drug label.